Financial Data and Key Metrics Changes - The company generated net revenue of $42.9 million in Q2 2020, a 111% increase from $20.3 million in Q2 2019, with approximately $19.7 million attributed to COVID-19 related equipment and supply sales [20] - Gross margin and EBITDA reached all-time highs of $25.9 million and $16.3 million respectively, although gross margins were affected by COVID-related product sales [23] - A tax benefit of $6.6 million was recorded due to the removal of a valuation allowance against deferred tax assets [24] - SG&A expenses totaled approximately $16.4 million, up from $11.5 million in the prior year [25] Business Line Data and Key Metrics Changes - Vent patient count declined slightly from Q1 but was up 8% compared to Q2 2019 [22] - Organic revenue growth was approximately 14% higher than Q2 2019, excluding COVID-19 impacts [21] - The company has pivoted to virtual training and inside sales, successfully hiring and training 7 new salespeople in new territories [8][10] Market Data and Key Metrics Changes - The company has seen a shift in demand for ventilators, with significant sales occurring in early epicenters like New York and Illinois, and now receiving requests from second-tier states [15][16] - The company is actively fulfilling requests for equipment and PPE, which could significantly contribute to Q3 revenue [16] Company Strategy and Development Direction - The company is focusing on technology investments, particularly in remote patient monitoring and the VieMed Connect app, to adapt to changing healthcare delivery methods [27] - A new call center for inside sales has been established to enhance communication with referral sources and patients [10] - The company aims to capitalize on relationships with hospitals through joint ventures and is targeting underserved markets with less than 5% market penetration [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the team's ability to adapt and innovate during the pandemic, positioning the company for future growth [39] - The company anticipates net revenue guidance for Q3 in the range of $31 million to $35 million, including $6.8 million to $9.8 million related to COVID-19 [33] - Management is optimistic about returning to historical growth rates once the pandemic subsides, citing ongoing demand for respiratory services [88] Other Important Information - The company has a solid balance sheet with approximately $29.7 million in cash and $11 million in accounts receivable [28] - The company is exploring both technology investments and potential inorganic growth opportunities, although technology solutions are currently the primary focus [78] Q&A Session Summary Question: Explanation of ventilator patient count decline despite revenue increase - Management explained that noncompliant patients were put on hold, allowing for increased revenue from compliant patients and equipment sales [46] Question: Future organic growth expectations - Management refrained from providing specific guidance but expressed a goal to return to historical growth rates through new technology and sales methods [48] Question: Progress with the VA and near-term revenue opportunities - Management remains optimistic about opportunities with the VA, noting new centers coming online and ongoing discussions with third-party payers [52] Question: Bad debt expense trends - Management indicated that low bad debt expense is a result of improved collection processes and effective workflow systems [61] Question: Conditions for CARES Act funding - Management clarified that the funds must be utilized for COVID-related expenses, which the company is well-positioned to demonstrate [64] Question: Adjustments in sales approach due to COVID - Management highlighted the shift to virtual communication and technology use, which has allowed for better patient management and engagement [71] Question: Future cash deployment strategies - Management confirmed that technology investments and equipment purchases are the primary focus for cash deployment, with inorganic opportunities considered but not prioritized [78] Question: Vent leasing program details - Management confirmed the introduction of a vent leasing program to assist hospitals struggling with cash flow, which is a new area of business for the company [102]

PART I - FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Viemed Healthcare, Inc.'s unaudited condensed consolidated financial statements and notes are presented for the specified periods [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The Condensed Consolidated Balance Sheets show the company's financial position, with total assets increasing significantly to $112.2 million at June 30, 2020, from $82.6 million at December 31, 2019 Condensed Consolidated Balance Sheet Highlights (in thousands of U.S. Dollars) | Metric | June 30, 2020 (Unaudited) | December 31, 2019 (Audited) | | :-------------------------------- | :-------------------------- | :-------------------------- | | Cash and cash equivalents | $29,707 | $13,355 | | Accounts receivable, net | $11,029 | $11,534 | | Inventory, net | $6,580 | $1,360 | | Total current assets | $49,207 | $27,811 | | Total assets | $112,178 | $82,596 | | Total current liabilities | $31,770 | $25,912 | | Total liabilities | $41,050 | $38,897 | | Total shareholders' equity | $71,128 | $43,699 | - Total assets increased by **$29.6 million (35.8%)** from December 31, 2019, to June 30, 2020[8](index=8&type=chunk) - Cash and cash equivalents more than doubled, increasing by **$16.3 million (122.5%)** over the six-month period[8](index=8&type=chunk) [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) The Condensed Consolidated Statements of Income and Comprehensive Income reveal substantial growth in revenue and net income for both the three and six months ended June 30, 2020, compared to the prior year Key Income Statement Data (in thousands of U.S. Dollars, except per share amounts) | Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | | :---------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Revenue | $42,854 | $20,325 | $66,660 | $38,440 | | Cost of revenue | $16,927 | $5,686 | $25,180 | $10,727 | | Gross profit | $25,927 | $14,639 | $41,480 | $27,713 | | Income from operations | $12,859 | $1,664 | $17,474 | $3,980 | | Net income | $19,412 | $1,326 | $23,655 | $3,284 | | Basic EPS | $0.50 | $0.04 | $0.62 | $0.09 | | Diluted EPS | $0.48 | $0.03 | $0.59 | $0.08 | - Revenue increased by **110.8%** for the three months and **73.4%** for the six months ended June 30, 2020, compared to the prior year[10](index=10&type=chunk) - Net income surged by **1363.9%** for the three months and **620.3%** for the six months ended June 30, 2020, primarily due to increased sales, gains on equipment disposal, and Provider Relief Funds[10](index=10&type=chunk) [Condensed Consolidated Statements of Changes in Shareholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Shareholders'%20Equity) The Condensed Consolidated Statements of Changes in Shareholders' Equity show an increase in total shareholders' equity from $43.7 million at December 31, 2019, to $71.1 million at June 30, 2020 Shareholders' Equity Changes (in thousands of U.S. Dollars) | Metric | December 31, 2019 | June 30, 2020 | | :-------------------------------------- | :---------------- | :------------ | | Total Shareholders' Equity | $43,699 | $71,128 | | Common Stock (Amount) | $3,366 | $8,414 | | Additional paid-in capital | $6,377 | $5,448 | | Retained earnings | $34,113 | $57,768 | | Common Shares Issued and Outstanding | 37,952,660 | 39,082,932 | - Net income contributed **$19.4 million** to retained earnings for the three months ended June 30, 2020, and **$23.7 million** for the six months ended June 30, 2020[12](index=12&type=chunk) - Stock-based compensation (options and restricted stock) added **$1.2 million** for the three months and **$2.3 million** for the six months ended June 30, 2020, to additional paid-in capital[12](index=12&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The Condensed Consolidated Statements of Cash Flows show a significant increase in net cash provided by operating activities to $22.0 million for the six months ended June 30, 2020, compared to $6.0 million in the prior year Key Cash Flow Data (in thousands of U.S. Dollars) | Cash Flow Activity | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | | :---------------------------------- | :----------------------------- | :----------------------------- | | Net cash provided by operating activities | $21,988 | $5,963 | | Net cash used in investing activities | $(620) | $(7,487) | | Net cash used in financing activities | $(5,016) | $(1,198) | | Net increase (decrease) in cash and cash equivalents | $16,352 | $(2,722) | | Cash and cash equivalents at end of period | $29,707 | $7,691 | - Operating cash flow significantly improved, driven by higher net income and non-cash adjustments, including a **$3.5 million** receipt from Provider Relief Funds[15](index=15&type=chunk)[181](index=181&type=chunk) - Investing activities used less cash in 2020 due to **$5.1 million** in proceeds from the sale of property and equipment related to COVID-19 response[15](index=15&type=chunk)[185](index=185&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) These notes provide detailed explanations and disclosures supporting the condensed consolidated financial statements, covering the company's business, accounting policies, debt, equity, and other financial commitments [1. Nature of Business and Operations](index=9&type=section&id=1.%20Nature%20of%20Business%20and%20Operations) Viemed Healthcare, Inc. is a provider of in-home durable medical equipment (DME) and post-acute respiratory healthcare services across over 35 U.S. states - Viemed Healthcare, Inc. provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services in over **35 states** in the United States[17](index=17&type=chunk) - As of June 30, 2020, the Company no longer qualifies as a 'foreign private issuer' and will become subject to U.S. domestic issuer rules effective January 1, 2021[18](index=18&type=chunk) - The Company is an 'emerging growth company' and has elected to comply with certain reduced U.S. public company reporting requirements[19](index=19&type=chunk) [2. Summary of Significant Accounting Policies](index=9&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) This section outlines the accounting principles, including GAAP compliance for interim reporting, the use of estimates, functional currency, and basis of consolidation - Financial statements are prepared in accordance with GAAP for interim financial information and SEC rules, reflecting management's estimates and assumptions[20](index=20&type=chunk)[24](index=24&type=chunk) - The COVID-19 pandemic's impacts on business, financial condition, and results of operations remain uncertain and difficult to predict, potentially affecting future estimates[25](index=25&type=chunk) Allowance for Doubtful Accounts (in thousands of U.S. Dollars) | Metric | June 30, 2020 | June 30, 2019 | | :---------------------- | :------------ | :------------ | | Balance, beginning of year | $7,782 | $4,266 | | Provision for bad debts | $5,578 | $3,859 | | Amounts written off | $(4,015) | $(1,251) | | Balance, end of period | $9,345 | $6,8

Viemed Healthcare, Inc. (NASDAQ:VMD) Q1 2020 Earnings Conference Call May 5, 2020 11:00 AM ET Company Participants William Zehnder - COO & Director Casey Hoyt - CEO & Director Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Nick Corcoran - Acumen Capital Doug Cooper - Beacon Securities Limited Operator Good day, and welcome to the Viemed First Quarter 2020 Earnings Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Todd Zehnder, ...

Revenue Performance - Total revenues for the three months ended March 31, 2020, were $23,806,000, representing a 31.1% increase from $18,115,000 in the same period of 2019[44]. - Revenue from ventilator rentals increased to $18,792,000 in Q1 2020 from $16,204,000 in Q1 2019, reflecting a growth of 15.8%[44]. - Revenue from COVID-19 response sales reached $1,040,000, with no comparable revenue in the prior year[44]. - Revenue for the quarter ended March 31, 2020, was $23.8 million, an increase from $21.4 million in the same quarter of 2019, representing an increase of 11%[143]. - For the three months ended March 31, 2020, revenue totaled $23.8 million, an increase of $5.7 million (or 31.4%) from the comparable period in 2019[146]. - COVID-19 response related sales amounted to $1.0 million, primarily from ventilators and associated supplies[148]. - Rental revenue from other durable medical equipment grew $1.3 million (or 167.4%) quarter over quarter[146]. Financial Position - The company's medical equipment net value as of March 31, 2020, was $56,632,000, up from $54,772,000 at the end of 2019[66]. - Total accrued liabilities decreased to $6,886,000 as of March 31, 2020, from $8,968,000 at the end of 2019, indicating a reduction of 24.1%[67]. - As of March 31, 2020, the Company had total notes payable of $8,951,000, down from $9,379,000 as of December 31, 2019[76]. - The Company reported net long-term notes payable of $7,179,000 as of March 31, 2020, compared to $7,629,000 at the end of 2019[76]. - The Company recognized finance lease liabilities of $9,763,000 as of March 31, 2020, a decrease from $10,132,000 as of December 31, 2019[77]. - Total assets as of March 31, 2020, were $86.8 million, up from $82.6 million at the end of 2019, showing a growth of 2.7%[143]. - The company had current assets of $30,151,000, compared to $27,811,000 as of December 31, 2019[111]. Income and Earnings - The net income attributable to shareholders for the three months ended March 31, 2020, was $4,243,000, compared to $1,958,000 for the same period in 2019[114]. - Basic earnings per share for the three months ended March 31, 2020, was $0.11, up from $0.05 in 2019[114]. - Net income for the quarter was $4.2 million, compared to $2.4 million for the same period in 2019, reflecting a year-over-year increase of 78%[143]. - For the quarter ended March 31, 2020, net income was $4.243 million, an increase from $2.388 million in the same quarter of 2019, representing a 77.5% year-over-year growth[160]. - Net income for the three months ended March 31, 2020 was $4.2 million, an increase of $2.3 million (or 116.7%) from the comparable period in 2019[155]. Expenses and Costs - Selling, general and administrative expenses totaled $10.6 million, an increase of $1.1 million (or 11.8%) from the comparable prior period, but as a percentage of revenue decreased to 44.4%[150]. - Cost of revenue totaled $8.3 million, an increase of $3.2 million (or 63.7%) from the comparable period in 2019, with gross profit percentage decreasing from approximately 72.2% to approximately 65.3%[149]. - Stock-based compensation for the three months ended March 31, 2020, totaled $1,151,000, compared to $880,000 for the same period in 2019[92]. - Stock-based compensation totaled $1.2 million, an increase of $0.3 million (or 30.8%) from the comparable period in 2019[152]. - Interest expense, net totaled $158,000, an increase of $132,000 (or 507.7%) from the comparable period in 2019[153]. Cash Flow and Financing - Cash and cash equivalents decreased to $8.4 million as of March 31, 2020, down from $13.4 million at December 31, 2019[162]. - Net cash provided by operating activities was $0.607 million for the three months ended March 31, 2020, compared to $0.650 million for the same period in 2019[163]. - Net cash used in financing activities was $3.842 million for the three months ended March 31, 2020, compared to $3.561 million in the same period of 2019[168]. - The company reported a net decrease in cash and cash equivalents of $4.946 million for the three months ended March 31, 2020[163]. - The company maintains a $10.0 million line of credit with Hancock Whitney Bank, which was fully available as of March 31, 2020[111]. Operational Highlights - The number of active ventilator patients at the end of the quarter was 7,965, an increase from 7,759 in the previous year, indicating a growth of 2.7%[143]. - The active ventilator patient base grew from 6,393 as of March 31, 2019 to 7,965 as of March 31, 2020, an increase of 25%[148]. - The company employed more than 255 licensed Respiratory Therapists, representing over 54% of the total employee count, to support its service model[132]. - The COVID-19 pandemic has led to minimal disruption in operations, with the company continuing to set up new patients in homes[134]. - The removal of non-invasive ventilators from the competitive bidding process is expected to last three years, allowing the company to furnish these products in all Medicare accredited areas[141]. Accounting and Compliance - The company has adopted ASU No. 2018-13 regarding fair value measurement, effective January 1, 2020, with no material impact on financial statements[61]. - The company is in compliance with all financial covenants as of March 31, 2020, with a total debt to adjusted EBITDA ratio of 0.83[173]. - The allowance for doubtful accounts was $10.2 million as of March 31, 2020, compared to $5.9 million as of March 31, 2019, indicating a significant increase in estimated uncollectible receivables[196]. - The company does not accept returns or refunds on equipment sales or sleep study services, and has no contract liabilities as of March 31, 2020[195]. - Deferred income tax assets and liabilities are recognized based on temporary differences between financial statement values and tax bases, requiring management estimates and assumptions[202].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-38973 Viemed Healthcare, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other juri ...

LEADING THE HEALTHCARE INDUSTRY IN HOME RESPIRATORY CARE IR PRESENTATION / DECEMBER 2019 FORWARD - LOOKING STATEMENTS This presentation (the "Presentation") about Viemed Healthcare, Inc. ("Viemed") is dated as of December 2019. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. No representa ...

Viemed Healthcare, Inc. (NASDAQ:VMD) Q3 2019 Results Earnings Conference Call November 5, 2019 11:00 AM ET Company Participants Todd Zehnder - Chief Operating Officer Casey Hoyt - Chief Executive Officer Conference Call Participants Sarah James - Piper Jaffray Brooks O'Neil - Lake Street Capital Markets Nick Corcoran - Acumen Capital Doug Cooper - Beacon Securities John Rakoto - Claret Asset Management Operator Please standby. We are about to begin. Good day everyone. Welcome to the Viemed third quarter 201 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-38973 Viemed Healthcare, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or o ...

Financial Data and Key Metrics Changes - The company generated revenue of $22.5 million in Q2 2019, a 45% increase from $15.5 million in Q2 2018 [26] - Active vet patients increased by 12% sequentially, reaching 7,130 by the end of the quarter [27] - Gross margin percentage rose to 75% from 73% in the prior year's second quarter [27] - Adjusted EBITDA totaled $4.6 million for the quarter, representing a 20% margin [27] Business Line Data and Key Metrics Changes - The percussion vest product line contributed to 11% of new patient growth [15] - The company launched a new oxygen business model, which is expected to drive more orders [16] - Compression therapy for lymphedema patients is being beta tested, with a U.S. market potential of over $4 billion, currently less than 20% penetrated [18] Market Data and Key Metrics Changes - The company is now licensed to operate in 44 states and Medicare approved in 38 states [11] - The company aims to expand its coverage to the lower 48 states within the next year [12] Company Strategy and Development Direction - The company is focused on organic growth through geographical expansion and enhancing its product offerings [14] - Plans to diversify payor mix and engage in value-based contracts are underway [23] - The company is preparing for competitive bidding zones expected in 2021 [49] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth opportunities driven by an aging population and increased patient volumes [42] - The company is investing in technology and new product lines to enhance service delivery and patient care [43] - Management anticipates revenue and gross margin to increase at a higher pace than SG&A expenses as investments normalize [33] Other Important Information - The company is now listed on both the Toronto Stock Exchange and NASDAQ, marking a significant milestone [24] - The company has invested in its workforce to support expanding programs, including new employees for the VA and pediatric division [29] Q&A Session Summary Question: Expansion Plans - The company is focusing on hiring qualified personnel within existing coverage areas to drive organic growth and prepare for competitive bidding zones [49] Question: SG&A Investments - Management indicated that some costs related to NASDAQ listing and technology investments are one-time, while ongoing costs will be associated with marketing and new product rollouts [53] Question: Economics of New Business Lines - The oxygen business is expected to have a margin profile around 20%, while compression therapy is projected to have gross margins in the 70% range [60][62] Question: VA Opportunities - Management is optimistic about penetrating the VA market, especially with the pilot study funded by the VA [68] Question: Bad Debt and Financial Metrics - Bad debt decreased to 7.7% from 10.4%, attributed to investments in billing and collections [72] Question: Future EBITDA Margins - Management expects adjusted EBITDA margins in the back half of the year to return to prior year levels, driven by organic revenue growth [75]

LEADING THE HEALTHCARE INDUSTRY IN HOME RESPIRATORY CARE IR PRESENTATION / AUGUST 2019 FORWARD - LOOKING STATEMENTS This presentation (the "Presentation") about Viemed Healthcare, Inc. ("Viemed") is dated as of August 2019. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. No representation ...